Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 13/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246144 | 0.80 | LMNA (0.39) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL3585234 | 0.73 | MTNR1A (0.43) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL4971001 | 0.70 | LMNA (0.52) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL11163328 | 0.68 | LMNA (0.37) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL28608699 | 0.68 | LMNA (0.37) | LMNATSHRMAPK1SCN4ASCN5A | |
| Bromide SCHEMBL11163151 | 0.67 | LMNA (0.36) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL31558693 | 0.65 | MEN1 (0.40) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL2402302 | 0.65 | MEN1 (0.40) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL28017429 | 0.64 | MEN1 (0.39) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL3253414 | 0.64 | MEN1 (0.42) | LMNATSHRMAPK1SCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166738-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-01-23 | — | — | US | disclosed |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | RPP30, PNP, RTF1 | LMNA 1159/4885TSHR 1773/4885MAPK1 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.